{"id":164421,"date":"2022-12-24T00:13:12","date_gmt":"2022-12-24T05:13:12","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/cytomx-therapeutics-to-outline-2023-company-priorities-and-provide-pipeline-update-on-january-5-2023\/"},"modified":"2024-08-18T11:46:34","modified_gmt":"2024-08-18T15:46:34","slug":"cytomx-therapeutics-to-outline-2023-company-priorities-and-provide-pipeline-update-on-january-5-2023","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cytomx-therapeutics-to-outline-2023-company-priorities-and-provide-pipeline-update-on-january-5-2023.php","title":{"rendered":"CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023"},"content":{"rendered":"<p><![CDATA[SOUTH SAN FRANCISCO, Calif., Dec.  22, 2022  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET \/ 2:00 p.m. PT to discuss updates.]]><\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/22\/2578939\/0\/en\/CytomX-Therapeutics-to-Outline-2023-Company-Priorities-and-Provide-Pipeline-Update-on-January-5-2023.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023\">CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Link: CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cytomx-therapeutics-to-outline-2023-company-priorities-and-provide-pipeline-update-on-january-5-2023.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164421","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164421"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164421"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164421\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}